Seeking Alpha

More on Celgene (CELG +1.8%) Q3: net profit +14% to $424.2M. Revlimid (blood-cancer) +18% to...

More on Celgene (CELG +1.8%) Q3: net profit +14% to $424.2M. Revlimid (blood-cancer) +18% to $970M, Vidaza (Blood cancer) +15% to $220M despite loss of patent protection in 2011. Raises FY EPS estimate to $4.85-$4.90 from increased July estimate of $4.80-$4.85 and vs consensus of $4.88; narrows revenue guidance to $5.45B-$5.55B vs consensus of $5.5B.
Comments (2)
  • kalfrey
    , contributor
    Comments (5) | Send Message
     
    I am a Revlilmid patient and there is a reason it is a $2b winner. Pipeline may be the best.
    25 Oct 2012, 10:15 PM Reply Like
  • kalfrey
    , contributor
    Comments (5) | Send Message
     
    I am a Revlimid patient. There is a reason it is a $2b winner. Pipeline may be the best.
    25 Oct 2012, 10:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|